A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000671 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: March 14, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT) in patients with AIDS or advanced AIDS-related complex (ARC) who have tolerated AZT therapy for 12 months or longer. Per amendment, asymptomatic patients with CD4 counts less than 200 cells/mm3 are eligible.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication of HIV with less apparent toxicity than AZT. Studies indicate that ddI remains active in the body for at least 12 hours; thus benefits of ddI might be achieved with a low frequency of drug administration.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Zidovudine Drug: Didanosine | Phase 2 |
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication of HIV with less apparent toxicity than AZT. Studies indicate that ddI remains active in the body for at least 12 hours; thus benefits of ddI might be achieved with a low frequency of drug administration.
Two dose levels of ddI, each adjusted depending on patient's weight at study entry, are compared with a variable dosage regimen of AZT (the dose which the patient is tolerating at the time of study entry). Randomization is stratified by baseline CD4 cell count (less than 100 or 100-300) and Medical Center. This study continues for at least 12 months after the entry of the first subject. Patients randomized to AZT will receive orally. All patients randomized to AZT also receive a ddI placebo at 12 hour intervals. Patients randomized to ddI receive AZT placebo.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 750 participants |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment |
Actual Primary Completion Date : | March 1992 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Required:
- Aerosolized pentamidine (300 mg every 4 weeks).
Allowed:
- Chronic suppressive treatment for toxoplasmosis, Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis, herpes simplex virus infection.
- Ganciclovir for patients developing cytomegalovirus (CMV) infection while in study.
- Erythropoietin for patients under the relevant treatment IND.
- Treatment of opportunistic infections with other than sulfonamide-containing regimens.
- Aspirin, acetaminophen, or non-steroidal anti-inflammatory agents is discouraged, but is permitted for as short a period of time as possible.
- Chronic use of trimethoprim - sulfamethoxazole or other sulfonamide preparations is not encouraged while on study.
Patients must:
- Have had the diagnosis of AIDS or advanced AIDS related complex (ARC).
- Have received AZT therapy for at least 12 months, with a minimal daily dose of 500 mg/day and with no more than 60 days off AZT therapy within the 12 month period; medical records with documentation of AZT dosing must be provided.
- Provide informed consent (guardian as appropriate).
- Be available for follow-up for at least 6 months.
- Have the inclusion laboratory values within approximately 14 days of initiating therapy (except for CD4 cell counts).
- Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 cell counts < 300 cells/mm3.
Allowed:
- Positive blood culture for Mycobacterium avium or Cytomegalovirus.
- Prior history of toxoplasmosis, Herpes simplex, Cryptococcus, or Pneumocystis carinii pneumonia (PCP) requiring chronic suppressive therapy.
- Occasional premature atrial or ventricular contractions.
Prior Medication:
Required:
- Zidovudine (AZT) therapy for at least 12 months, with a minimal daily dose of 500 mg/day, and with no more than 60 days off AZT therapy within the 12-month period (documentation of AZT dosing must be provided).
Allowed:
- Intralesional agents.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
- AIDS-dementia complex = or > stage 2.
- Active AIDS defining opportunistic infections not specifically allowed.
- Intractable diarrhea.
- Grade 2 neuropathy, based on the Neuropathy Targeted Symptom Questionnaire, or any moderate abnormality indicative of peripheral neuropathy, particularly impaired sensation of sharp pain, light touch, or vibration in the lower extremities, distal extremity weakness, or distal extremity hyperreflexia.
- Prior history of acute pancreatitis within past 2 years or chronic pancreatitis.
- History of seizures within past 2 years or currently requiring anticonvulsants for control.
- History of past or current heart disease.
- Malignancy likely in the investigator's opinion to require cytotoxic chemotherapy during the expected course of this trial.
- Life expectancy < 3 months.
Concurrent Medication:
Excluded:
- Isoniazid (INH). Neurotoxic drugs. Oral acidifying agents.
Patients with the following are excluded:
- Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
- AIDS-dementia complex = or > stage 2.
- Active AIDS defining opportunistic infections not specifically allowed.
- Intractable diarrhea.
- Prior history of acute pancreatitis within past 2 years or chronic pancreatitis.
- History of seizures within past 2 years or currently requiring anticonvulsants for control.
- History of past or current heart disease.
- Malignancy likely in the investigator's opinion to require cytotoxic chemotherapy during the expected course of this trial.
- Life expectancy = or < 3 months.
- Previous participation in any study of ddI, ddC or d4T.
Prior Medication:
Excluded:
- Ganciclovir (DHPG).
- Excluded within 1 month of study entry:
- ddI and any other antiretroviral drug or investigational anti-HIV agent except for zidovudine (AZT).
Interferons.
- Immunomodulating drugs.
- Cytotoxic agents not specifically allowed.
- Neurotoxic drugs.
Excluded within 3 months of study entry:
- Ribavirin.
Prior Treatment:
Excluded within 14 days of study randomization:
- Blood transfusion.
Active alcohol or drug abuse that is sufficient, in investigator's opinion, to prevent adequate compliance with study therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000671

Study Chair: | J Kahn | ||
Study Chair: | D Richman |
Publications:
ClinicalTrials.gov Identifier: | NCT00000671 History of Changes |
Other Study ID Numbers: |
ACTG 117 070V1 AI454-009 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | March 14, 2011 |
Last Verified: | August 1992 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Didanosine Zidovudine |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Slow Virus Diseases Zidovudine Didanosine Antimetabolites Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents |